Strategic Focus on Rare CNS Disorders: The company targets severe, monogenic central nervous system (CNS) disorders, which often have high unmet medical needs and potential for orphan drug designations, leading to a more streamlined regulatory path and market exclusivity if successful.

Robust Gene Therapy Pipeline: Passage Bio possesses a pipeline of AAV-delivered gene therapies targeting specific rare genetic CNS diseases, with lead programs addressing conditions like GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy, some of which are in clinical development.

Foundational Collaboration with UPenn: A strong, foundational relationship with the University of Pennsylvania's Gene Therapy Program (GTP), a pioneer in gene therapy, provides access to cutting-edge research, intellectual property, and experienced scientific talent.